



I hereby certify that this is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 019934-001620US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On: March 24, 2004
By: Tara N. Damhoff
Tara N. Damhoff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHALL and PENFOLD

Application No.: 10/681,478

Filed: 10/08/2003

For: METHODS AND COMPOSITIONS
USEFUL FOR STIMULATING AN
IMMUNE RESPONSE

Examiner: NOT YET ASSIGNED

Art Unit: NOT YET ASSIGNED

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. This application is a continuation application and claims priority to U.S. Appl. No. 10/061,943, filed February 1, 2002 (the "parent application"). All of the references, except B19, were submitted to or cited by the U.S. Patent and Trademark Office in the parent application. Therefore, a copy of reference B19 is enclosed, and copies of the remaining references are not enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Scott Ausenhus", written over the typed name.

Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:tnd
60055402 v1



Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/681,478	
			Filing Date	10-08-2003	
			First Named Inventor	Schall, Thomas J.	
			Art Unit	NOT YET ASSIGNED	
			Examiner Name	NOT YET ASSIGNED	
Sheet	1	of	8	Attorney Docket Number	019934-001620US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	A1	US-3,379,729	04/23/1968	M. Protiva et al.	
	A2	US-5,529,771	06/25/1996	Hooks et al.	
	A3	US-5,652,133	07/29/1997	Murphy	
	A4	US-5,665,362	09/09/1997	Inglis et al.	
	A5	US-5,720,957	02/24/1998	Jones et al.	
	A6	US-5,753,476	05/19/1998	Jones et al.	
	A7	US-5,756,264	05/26/1998	Schwartz et al.	
	A8	US-5,763,217	06/09/1998	Cynader et al.	
	A9	US-5,824,318	10/20/1998	Mohr et al.	
	A10	US-5,843,458	12/01/1998	Jones	
	A11	US-5,846,806	12/08/1998	Jones et al.	
	A12	US-5,866,136	02/02/1999	Ramshaw et al.	
	A13	US-5,877,004	03/02/1999	Jones et al.	
	A14	US-5,908,780	06/01/1999	Jones	
	A15	US-5,939,320	08/17/1999	Littman et al.	
	A16	US-5,948,775	09/07/1999	Koko et al.	
	A17	US-5,965,697	10/12/1999	Czaplewski et al.	
	A18	US-5,998,160	12/07/1999	Berens	
	A19	US-6,028,169	02/22/2000	Kreider et al.	
	A20	US-6,031,080	02/29/2000	Williams, et al.	
	A21	US-6,033,671	03/07/2000	Frueh et al.	
	A22	US-6,034,102	03/07/2000	Aiello	
	A23	US-6,051,375	04/18/2000	Rose et al.	
	A24	US-6,051,428	04/18/2000	Fong et al.	
	A25	US-6,150,132	11/21/2000	Wells et al.	
	A26	US-6,420,121 B1	07/16/2002	J. Nelson et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/681,478	
			Filing Date	10-08-2003	
			First Named Inventor	Schall, Thomas J.	
			Art Unit	NOT YET ASSIGNED	
			Examiner Name	NOT YET ASSIGNED	
Sheet	2	of	8	Attorney Docket Number	019934-001620US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	EPO	EP 0 277 773	A1	10/08/1988			<input type="checkbox"/>
	B2	PCT	WO 94/11504	A1	05/26/1994			<input type="checkbox"/>
	B3	PCT	WO 96/23068	A1	08/01/1996			<input type="checkbox"/>
	B4	PCT	WO 98/02151	A2	01/22/1998			<input type="checkbox"/>
	B5	PCT	WO 98/11073	A2	01/22/1998			<input type="checkbox"/>
	B6	PCT	WO 99/00510	A1	01/07/1999			<input type="checkbox"/>
	B7	PCT	WO 99/09178	A1	02/25/1999			<input type="checkbox"/>
	B8	PCT	WO 99/27122	A1	06/03/1999			<input type="checkbox"/>
	B9	PCT	WO 99/36562	A1	07/22/1999			<input type="checkbox"/>
	B10	PCT	WO 99/36568	A2	07/22/1999			<input type="checkbox"/>
	B11	PCT	WO 99/61472	A1	12/02/1999			<input type="checkbox"/>
	B12	PCT	WO 00/00491	A1	01/06/2000			<input type="checkbox"/>
	B13	PCT	WO 00/06203	A1	02/10/2000			<input type="checkbox"/>
	B14	PCT	WO 02/17900	A2	03/07/2000			<input type="checkbox"/>
	B15	PCT	WO 00/11950	A1	03/09/2000			<input type="checkbox"/>
	B16	PCT	WO 00/34494	A1	06/15/2000			<input type="checkbox"/>
	B17	PCT	WO 02/17969	A2	03/07/2001			<input type="checkbox"/>
	B18	PCT	WO 02/18954	A2	03/07/2002			<input type="checkbox"/>
	B19	PCT	WO 02/062296	A2	08/15/2002			<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60055402 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/681,478
				Filing Date	10-08-2003
				First Named Inventor	Schall, Thomas J.
				Art Unit	NOT YET ASSIGNED
				Examiner Name	NOT YET ASSIGNED
Sheet	3	of	8	Attorney Docket Number	019934-001620US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	BEISSER, P.S., ET AL.; Viral Chemokine Receptors and Chemokines in Human Cytomegalovirus Trafficking and Interaction with the Immune System; <i>Current Topics in Microbiology and Immunology</i> ; 2002; pp. 203-234; Vol. 269; Springer; Berlin, DE.		
	C2	BEISSER, PATRICK S., et al.; Deletion of the R78 G Protein-Coupled Receptor Gene from Rat Cytomegalovirus Results in an Attenuated, Syncytium-Inducing Mutant Strain; <i>Journal of Virology</i> ; September 1999; pp. 7218-7230; Vol. 73, No. 9		
	C3	BEISSER, PATRICK S., et al.; The R33 G Protein-Coupled Receptor Gene of Rat Cytomegalovirus Plays an Essential Role in the Pathogenesis of Viral Infection; <i>Journal of Virology</i> ; March 1998; pp. 2352-2363; Vol. 72, No. 3		
	C4	BILLSTROM, MARCELLA A. et al.; Intracellular Signaling by the Chemokine Receptor US28 during Human Cytomegalovirus Infection; <i>Journal of Virology</i> ; July 1998; pp. 5535-5544; Vol. 72, No. 7		
	C5	BODAGHI, BAHRAM, et al.; Chemokine Sequestration by Viral Chemoreceptors as a Novel Viral Escape Strategy: Withdrawal of Chemokines from the Environment of Cytomegalovirus-infected Cells; <i>J. Exp. Med.</i> ; September 7, 1998; pp. 855-866; Vol. 188, No. 5		
	C6	BORST, M.E., et al.; Development of a cytomegalovirus vector for somatic gene therapy; <i>Bone Marrow Transplantation</i> ; 2000; pp. S80-S82; Supp. 2		
	C7	BRANCH, ANDREA D.; A good antisense molecule is hard to find; <i>TIBS</i> 23; February 1998; pp. 45-50		
	C8	CHA, TAI-AN, et al.; Human Cytomegalovirus Clinical Isolates Carry at Least 19 Genes Not Found in Laboratory Strains; <i>Journal of Virology</i> ; January 1996; pp. 78-83; Vol. 70, No. 1		
	C9	CHEE, M.S., et al.; Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169; <i>Current Topics in Microbiology and Immunology</i> ; 1990; pp. 126-169; Vol. 154		
	C10	CHEE, M.S., et al.; Human cytomegalovirus encodes three G protein-coupled receptor homologues; <i>Nature</i> ; April 19, 1990; pp. 774-777; Vol. 344		
	C11	CRAIGEN, J.L., et al.; Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration; <i>Immunology</i> ; 1997; pp. 138-145; Vol. 92		
	C12	CROOKE, STANLEY T. et al.; <i>Antisense Research and Applications; Basic Principles of Antisense Therapeutics</i> ; chapters 1-3; pp. 1-53		
	C13	CRYSTAL, RONALD G.; Transfer of Genes to Humans: Early Lessons and Obstacles to Success; <i>Science</i> ; pp. 404-410; 20 October 1995; Vol. 270;		
	C14	DAVIS-POYNTER, Nicholas J., et al.; Identification and Characterization of a G Protein-Coupled Receptor Homolog Encoded by Murine Cytomegalovirus; <i>Journal of Virology</i> ; February 1997; pp. 1521-1529; Vol. 71, No. 2		
	C15	DAVIS-POYNTER, Nicholas J., et al.; Masters of deception: A review of herpesvirus immune evasion strategies; <i>Immunology and Cell Biology</i> ; 1996; pp. 513-522; Vol. 74		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/681,478	
			Filing Date	10-08-2003	
			First Named Inventor	Schall, Thomas J.	
			Art Unit	NOT YET ASSIGNED	
			Examiner Name	NOT YET ASSIGNED	
Sheet	4	of	8	Attorney Docket Number	019934-001620US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C16	FARRELL, H.E., et al.; Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue <i>in vivo</i> ; <i>Nature</i> ; April 3, 1997; pp. 510-514; Vol. 386		
	C17	FLEMING, PETER, et al.; The Murine Cytomegalovirus Chemokine Homolog, m131/129, Is a Determinant of Viral Pathogenicity; <i>Journal of Virology</i> ; August 1999; pp. 6800-6809; Vol. 73, No. 8		
	C18	FRANCKEN, BART J.B., et al.; Human 5-Hydroxytryptamine _{5A} Receptors Activate Coexpressed G _i and Go Proteins in <i>Spodoptera frugiperda</i> 9 Cells; <i>Molecular Pharmacology</i> ; pp. 1034-1044; May 2000; Vol. 57, No. 5		
	C19	GAO, JI-LIANG; et al.; Human Cytomegalovirus Open Reading Frame US28 Encodes a Functional γ Chemokine Receptor; <i>The Journal of Biological Chemistry</i> ; November 18, 1994; pp. 28539-28542; Vol. 269, No. 46		
	C20	GenBank Accession No.: X17403; 10 February 1999		
	C21	GenBank Accession No.: X53293; 1 December 1992		
	C22	GenBank Accession No: AF073831; 23 June 2000		
	C23	GenBank Accession No: AF073832; 23 June 2000		
	C24	GenBank Accession No: AF073833; 23 June 2000		
	C25	GenBank Accession No: AF073834; 23 June 2000		
	C26	GenBank Accession No: AF073835; 23 June 2000		
	C27	GenBank Accession No: L20501; 2 May, 1996		
	C28	GILBERT, MARK J., et al.; Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product; <i>Nature</i> ; 24 October 1996; pp. 720-722; Vol. 383		
	C29	GOMPELS, U.A.; et al.; The DNA Sequence of Human Herpesvirus-6: Structure, Coding Content, and Genome Evolution; <i>Virology</i> ; 1995; pp. 29-51; Vol. 209		
	C30	GRUNDY, JANE E., et al.; Cytomegalovirus-Infected Endothelial Cells Recruit Neutrophils by the Secretion of C-X-C Chemokines and Transmit Virus by Direct Neutrophil-Endothelial Cell Contact and during Neutrophil Transendothelial Migration; <i>The Journal of Infectious Diseases</i> ; 1998; pp. 1465-1474; Vol. 177		
	C31	HA, HUNJOO, et al.; Atherogenic lipoproteins enhance mesangial cell expression of platelet-derived growth factor: Role of protein tyrosine kinase and cyclic AMP-dependent protein kinase A; <i>J Lab Clin Med</i> ; pp. 456-465; May 1998; Vol. 131, No. 5		
	C32	HARRISON, JEFFREY K., et al.; Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia; <i>Proc. Natl. Acad. Sci. USA</i> ; September 1998; pp. 10896-10901; Vol. 95		
	C33	HIRSCH, ALEC J., et al.; Human Cytomegalovirus Inhibits Transcription of the CC Chemokine MCP-1 Gene; <i>Journal of Virology</i> ; January 1999; pp. 404-410; Vol. 73, No. 1		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/681,478
				Filing Date	10-08-2003
				First Named Inventor	Schall, Thomas J.
				Art Unit	NOT YET ASSIGNED
				Examiner Name	NOT YET ASSIGNED
Sheet	5	of	8	Attorney Docket Number	019934-001620US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C34	HUMAR A., et al.; Elevated Serum Cytokines Are Associated with Cytomegalovirus Infection and Disease in Bone Marrow Transplant Recipients; <i>The Journal of Infectious Diseases</i> ; 1999; pp. 484-488; Vol. 179		
	C35	HWANG, EUNG-SOO, et al.; Induction of Neutralizing Antibody Against Human Cytomegalovirus (HCMV) with DNA-Mediated Immunization of HCMV Glycoprotein B in Mice; <i>Microbiol. Immunol.</i> ; 1999; pp. 307-310; Vol. 43, No. 3		
	C36	ISEGAWA, YUJI, et al.; Human Herpesvirus 6 Open Reading Frame U12 Encodes a Functional γ -Chemokine Receptor; <i>Journal of Virology</i> ; July 1998; pp. 6104-6112; Vol. 72, No. 7		
	C37	KLEDAL, THOMAS N., et al.; Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28; <i>FEBS Letters</i> ; 1998; pp. 209-214; Vol. 441, Elsevier Science Publishers, Amsterdam, NL.		
	C38	KLEDAL, THOMAS N.; et al.; A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus; <i>Science</i> ; 12 September 1997; pp. 1656-1659; Vol. 277		
	C39	KLEIJNEN, MAURITS F., et al.; A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface; <i>EMBO Journal</i> ; 1997, pp. 685-694; Vol. 16, No. 4		
	C40	KOTENKO, SERGEI, et al.; Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10); February 15, 2000, pp. 1695-1700, Vol. 97, No. 4		
	C41	KOYAMA, NORIYUKI, et al.; Heparan Sulfate Proteoglycans Mediate a Potent Inhibitory Signal for Migration of Vascular Smooth Muscle Cells; <i>Circulation Research</i> ; pp. 305-313; August 10, 1998; Vol. 83, No. 3		
	C42	KRAUSE, PHILIP R., et al.; Herpesvirus Vaccines: Development, Controversies, and Applications; New Vaccines and New Vaccine Technology; March 1999; pp. 61-81; Vol. 13, No. 1		
	C43	KRAVITZ, RACHEL H., et al.; Cloning and characterization of rhesus cytomegalovirus glycoprotein B; <i>Journal of General Virology</i> ; 1997; pp. 2009-2013; Vol. 78		
	C44	KROPFF, BARBARA, et al.; Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein; <i>Journal of General Virology</i> ; 1997; pp. 1999-2007		
	C45	KUHN, DONALD, E., et al.; The Cytomegalovirus US28 Protein Binds Multiple CC Chemokines with High Affinity; <i>Biochemical and Biophysical Research Communications</i> ; June 6, 1995; pp. 325-330; Vol. 211, No. 1		
	C46	KUNG, H.F., et al.; Dopamine D-2 Receptor Imaging Radiopharmaceuticals: Synthesis, Radiolabeling, and in Vitro Binding of (R)-(+)- and (S)-(-)-3- Iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidiny) methyl] benzamide; <i>Journal of Medical Chemistry</i> ; pp.1039-1042; 1988; Vol. 31, No. 5		
	C47	LOCKRIDGE, KRISTEN M.; et al.; Primate Cytomegaloviruses Encode and Express an IL-10-like Protein; <i>Virology</i> ; 2000; pp. 272-280; Vol. 268		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/681,478
				Filing Date	10-08-2003
				First Named Inventor	Schall, Thomas J.
				Art Unit	NOT YET ASSIGNED
				Examiner Name	NOT YET ASSIGNED
Sheet	6	of	8	Attorney Docket Number	019934-001620US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C48	MAHALINGAM, SURENDRAN, et al.; Chemokines and chemokine receptors in infectious diseases; <i>Immunology and Cell Biology</i> ; 1999; pp. 469-475; Vol. 77		
	C49	MANNING, WILLIAM et al. "Use of recombinant murine cytomegalovirus expressing vesicular stomatitis virus G protein to pseudotype retroviral vectors" <i>J. Virological Methods</i> , 1998, pp. 31-39, Vol. 73.		
	C50	MARGULIES, BARRY J., et al.; Identification of the Human Cytomegalovirus G. Protein-Coupled Receptor Homologue Encoded by UL33 in Infected Cells and Enveloped Virus Particles; <i>Virology</i> ; 1996; pp. 111-125; Vol. 225		
	C51	MARTIN, W. JOHN; Chemokine Receptor-Related Genetic Sequences in an African Green Monkey Simian Cytomegalovirus-Derived Stealth Virus; <i>Experimental and Molecular Pathology</i> ; 2000; pp. 10-16;		
	C52	MCNALL, STEVEN J., et al.; Novel Serotonin Receptors in <i>Fasciola</i> . Characterization by Studies on Adenylate Cyclase Activation and [3H]LSD Binding; <i>Biochemical Pharmacology</i> ; pp.2789-2797; 1984; Vol. 33, No. 17		
	C53	MICHELSON, S., Interaction of Human Cytomegalovirus with Monocytes/Macrophages: A Love-Hate Relationship; <i>Path. Biol.</i> ; 1997; pp. 146-158; Vol. 45, No. 2		
	C54	MICHELSON, SUSAN, et al.; Modulation of RANTES Production by Human Cytomegalovirus Infection of Fibroblasts; <i>Journal of Virology</i> ; September 1997; pp. 6495-6500; Vol. 71, No. 9		
	C55	MICHELSON, SUSAN; Cytomegalovirus (CMV) and sequestration of chemokines; <i>Eur. Cytokine Netw.</i> ; June 1999; pp. 286-287; Vol. 10, No. 2		
	C56	MONTI, GIANPAOLA, et al.; Intrapulmonary Production of RANTES During Rejection and CMV Pneumonitis After Lung Transplantation; <i>Transplantation</i> ; June 27, 1996; pp. 1757-1762; Vol. 61, No.12		
	C57	MURAYAMA, TSUGIYA, et al.; Potential Involvement of IL-8 in the pathogenesis of human cytomegalovirus infection; <i>Journal of Leukocyte Biology</i> ; July 1998; pp. 62-67; Vol. 64		
	C58	NEOTE, KULDEEP, et al. Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor; <i>Cell</i> ; February 12, 1993; pp. 415-525; Vol. 72		
	C59	NISHIYORI, ATSUSHI, et al.; Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?; <i>FEBS Letters</i> ; 1998; pp. 167-172; Vol. 429		
	C60	NORDØY,INGVILD, et al.; Immunologic Parameters as Predictive Factors of Cytomegalovirus Disease in Renal Allograft Recipients; <i>The Journal of Infectious Diseases</i> ; 1999; pp. 195-198; vol. 180		
	C61	PADIA, J.K., et al.; Novel Nonpeptide CCK-B Antagonists: Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists; <i>Journal of Medicinal Chemistry</i> ; pp. 1042-1049; 1998; Vol. 41, No. 7		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/681,478		
		Filing Date	10-08-2003		
		First Named Inventor	Schall, Thomas J.		
		Art Unit	NOT YET ASSIGNED		
		Examiner Name	NOT YET ASSIGNED		
Sheet	7	of	8	Attorney Docket Number	019934-001620US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C62	PADIA, J.K., et al; Design and Synthesis of Novel Nonpeptide CCK-B Receptor Antagonists; <i>Bioorganic & Medicinal Chemistry Letters</i> ; pp. 805-810; 1997; Vol. 7, No. 7		
	C63	PALÙ, GIORGIO, et al.; In pursuit of new developments for gene therapy of human diseases; <i>Journal of Biotechnology</i> ; pp. 1-13; 1999; Vol. 68		
	C64	PASS, ROBERT F., et al.; A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B. and a New Adjuvant; <i>The Journal of Infectious Diseases</i> ; 1999; pp. 970-975; Vol. 180		
	C65	PENFOLD, MARK E.T.; et al.; Cytomegalovirus encodes a potent γ chemokine; <i>Proc. Natl. Acad. Sci. USA</i> ; August 1999; pp. 9839-9844; Vol. 96		
	C66	PLESKOFF, OLIVIER, et al; The Cytomegalovirus-Encoded Chemokine Receptor US28 Can Enhance Cell-Cell Fusion Mediated by Different Viral Proteins; <i>Journal of Virology</i> ; August 1998; pp. 6389-6397; Vol. 72, No. 8		
	C67	QUINNAN Jr., M.D., GERALD V., et al.; Comparative Virulence and Immunogenicity of the Towne Strain and a Nonattenuated Strain of Cytomegalovirus; <i>Annals of Internal Medicine</i> ; 1984; pp. 478-483; Vol. 101		
	C68	RAWLINSON, WILLIAM D., et al.; Analysis of the Complete DNA Sequence of Murine Cytomegalovirus; <i>Journal of Virology</i> ; December 1996; pp. 8833-8849; Vol. 70, No. 10		
	C69	REUSCH, UWE, et al.; A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation; <i>EMBO Journal</i> ; 1999; pp. 1081-1091; Vol. 18, No. 4		
	C70	REYBURN, HUGH T., et al.; The Class I MHC homologue of Human Cytomegalovirus inhibits attack by natural killer cells; <i>Nature</i> ; 3 April 1997; pp. 514-517; Vol 386		
	C71	ROLLINS, BARRETT J.; Chemokines; <i>Blood</i> ; August 1, 1997; pp. 909-928; Vol. 90, No. 3		
	C72	SAEDERUP, NOAH, et al.; Cytomegalovirus-encoded γ chemokine promotes monocyte-associated viremia in the host; <i>Proc. Natl. Acad. Sci. USA</i> ; September 1999; pp. 10881-10886; Vol. 96		
	C73	SALLUSTO, FEDERICA, et al.; Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses; <i>Immunology Today</i> ; December 1998; pp. 568-574; Vol. 19, No. 12		
	C74	SCHALL, T.J., et al.; Biology of the Rantes/SIS Cytokine Family; <i>Cytokine</i> ; pp. 165-183; May 1991; Vol. 3, No. 3		
	C75	SCHOFIELD, J.P., et al.; Non-viral approaches to gene therapy; <i>British Medical Bulletin</i> ; pp. 56-71; 1995; Vol. 51, No. 1		
	C76	SEOW, HENG-FONG; Pathogen interactions with cytokines and host defence: an overview; <i>Veterinary Immunology and Immunopathology</i> ; 1998; pp. 139-148; Vol. 63		
	C77	SHELLAM, G.R.; The Potential of Murine Cytomegalovirus as a Viral Vector for Immunocontraception; <i>Reprod. Fertil. Dev.</i> ; 1994; pp. 401-409; Vol. 6		
	C78	STREBLOW, DANIEL N., et al.; The Human Cytomegalovirus Chemokine Receptor US28 Mediates Vascular Smooth Muscle Cell Migration; <i>Cell</i> ; November 24, 1999; pp. 511-520; Vol. 99		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/681,478
				Filing Date	10-08-2003
				First Named Inventor	Schall, Thomas J.
				Art Unit	NOT YET ASSIGNED
				Examiner Name	NOT YET ASSIGNED
Sheet	8	of	8	Attorney Docket Number	019934-001620US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C79	SWISS-PROT Accession No. P16849; 1 August 1990		
	C80	THÄLE, REGINE, et al.; Identification and Expression of an Murine Cytomegalovirus Early Gene Coding for an Fc Receptor; <i>Journal of Virology</i> ; December 1994; pp. 7757-7765; Vol. 68, No. 12		
	C81	TOMASEC, PETER, et al.; Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40; <i>Science</i> ; February 11, 2000; pp. 1031-1033; Vol. 287		
	C82	VERMA, INDER M., et al.; Gene therapy - promises, problems and prospects; <i>Nature</i> ; pp. 239-242; 18 September 1997; Vol. 389		
	C83	VIEIRA, JEFFREY, et al.; Functional Analysis of the Human Cytomegalovirus US28 Gene by Insertion Mutagenesis with the Green Fluorescent Protein Gene; <i>Journal of Virology</i> ; October 1998; pp. 8158-8165; Vol. 72, No. 10		
	C84	WANG, T.S., et al.; A Simple Method of Preparation for [123I]-(S)-(-)-IBZM; <i>Applied Radiation and Isotopes</i> ; pp. 369-372; 1998; Vol. 49, No. 4		
	C85	WARD, STEPHEN G., et al.; Chemokines and T Lymphocytes: More than an Attraction; <i>Immunity</i> ; July 1998; pp. 1-11; Vol. 9		
	C86	ZIEGLER, HEIKE, et al.; A mouse Cytomegalovirus Glycoprotein Retains MHC Class I Complexes in the ERGIC/cis-Golgi Compartments; <i>Immunity</i> ; January 1997; pp. 57-66; Vol. 6		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.